Trevi Therapeutics, Inc. TRVI Granted (in shares)
Granted (in shares) at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s granted (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s granted (in shares)?
- Trevi Therapeutics, Inc. (TRVI) reported granted (in shares) of $10.66 in Q1 2026.
- How has Trevi Therapeutics, Inc.'s granted (in shares) changed year-over-year?
- Trevi Therapeutics, Inc.'s granted (in shares) increased by 152.0% year-over-year, from $4.23 to $10.66.
- What does granted (in shares) mean?
- The weighted average exercise price of stock options granted to employees and directors during the reporting period. This metric reflects the company's cost of equity-based incentives and the strike price set for new option awards.